Bronchodilators remain central to the symptomatic management of chronic obstructive
pulmonary disease and asthma, and, for this reason and also because the patent protection …

Bronchodilators are central in the treatment of of airways disorders. They are the mainstay of
the current management of chronic obstructive pulmonary disease (COPD) and are critical in …

Introduction: Inhaled bronchodilators are the mainstay of the current management of COPD
at all stages of the disease, and are critical in the symptomatic management of asthma …

Because of the central role of bronchodilators in the treatment of respiratory diseases, there
is still considerable interest in finding novel classes of broncholytic drugs. It can be …

Bronchodilators remain the cornerstone of the treatment of airway disorders such as asthma
and chronic obstructive pulmonary disease (COPD). There is therefore considerable interest …

Inhaled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and
long-acting β2-adrenoreceptor agonists (LABA), are the mainstay of pharmacological …

An important step in simplifying asthma and chronic obstructive pulmonary disease (COPD)
management and improving adherence with prescribed therapy is to reduce the dose …

Bronchodilator drugs are consumed frequently, and often regularly for long periods. Current
sales figures for fl-agonist aerosols in the United Kingdom suggest that everyday there are …

Novel long-acting β 2-agonists (eg indacaterol, vilanterol, olodaterol and carmoterol) and
muscarinic antagonists (eg tiotropium, aclidinium, glycopyrronium and umeclidinium …

Inhaled bronchodilators, including beta2-agonists and antimuscaric receptor antagonists,
are the mainstay of pharmacotherapy in chronic obstructive pulmonary disease (COPD). The …